2 H5]phenylalanine (P Ͼ 0.05). Our findings confirm that the postprandial MPS assessed using the primed continuous tracer infusion approach may differ if tracer steady-state conditions in the precursor pools are perturbed. The use of intrinsically doubly labeled protein provides a method to study the metabolic fate of the ingested protein and the subsequent postprandial MPS response. dietary protein; nutrition; stable isotopes; hypertrophy VARIOUS METHODS have been applied to investigate the impact of food intake on postprandial muscle protein anabolism. The measurement of the phosphorylation status of key anabolic signaling molecules (e.g., mTORC1, p70S6K) in muscle biopsies collected before and after food intake does not seem to provide much insight into the postprandial stimulation of muscle protein accretion as they only represent static single point measurements (13, 21) . Therefore, the more preferred approach is the application of primed constant intravenous infusions with stable isotope-labeled amino acids to assess the dynamics of muscle protein synthesis during the postprandial phase (30).
VARIOUS METHODS have been applied to investigate the impact of food intake on postprandial muscle protein anabolism. The measurement of the phosphorylation status of key anabolic signaling molecules (e.g., mTORC1, p70S6K) in muscle biopsies collected before and after food intake does not seem to provide much insight into the postprandial stimulation of muscle protein accretion as they only represent static single point measurements (13, 21) . Therefore, the more preferred approach is the application of primed constant intravenous infusions with stable isotope-labeled amino acids to assess the dynamics of muscle protein synthesis during the postprandial phase (30) .
The calculation of muscle protein fractional synthesis rate (FSR), a direct measurement of muscle protein synthesis, assumes that the tracer labeling in the precursor pools (extracellular plasma free, muscle intracellular free, or aminoacyltRNA) remain in a relative steady state during the infusion protocol between muscle biopsy collections. The ingestion of dietary protein during the infusion makes it impossible to maintain tracer steady state which is required for the calculation of muscle protein FSR. The appearance of dietary proteinderived amino acids into the circulation following dietary protein digestion and absorption dilutes the labeling of the precursor pool amino acids and thus modulates the calculated muscle protein FSR. As a strategy to maintain steady-state labeling in the precursor pools for the use of precursor product equations, some workers add small amounts of free amino acid tracers to the dietary protein source (8) and/or provide small repeated boluses of protein (17) . This should allow the plasma enrichment level (typically ϳ4 -8% trace-to-tracee ratio) to be maintained following the ingestion of protein (8) . However, the timing and efficiency of intestinal digestion and/or amino acid absorption is quite different following the ingestion of crystalline-free amino acids compared with the ingestion of intact dietary protein (4) . Therefore, the addition of labeled-free amino acids to a protein containing meal with the intention to minimize disturbances in the precursor pool tracer enrichment during the continuous amino acid tracer infusion does not provide a reliable methodology to assess dietary proteinderived amino acid kinetics in vivo in humans (8) .
The production of intrinsically labeled dietary protein provides an effective tool to directly measure the rates of appearance of dietary protein-derived amino acids in the systemic circulation in vivo in humans (3, 26, 34) . Recently, we produced highly L- [1- 13 C]phenylalanine-labeled milk protein [Ͼ30 mole percent excess (MPE)] which can be used to assess the use of dietary protein-derived amino acids for de novo muscle protein accretion in the consumer (25, 35) . Of course, the ingestion of intrinsically L- [1- 13 C]phenylalanine-labeled milk proteins in combination with a primed constant intravenous infusion of L-[ring- 2 H 5 ]phenylalanine for the in vivo measurement of amino acid kinetics after a single meal and subsequent postprandial muscle protein synthesis will also result in the dilution of the L-[ring-2 H 5 ]phenylalanine precursor pool (23, 24, 25 The aim of our study was to assess the impact of the precursor pool dilution on the measurement of postprandial myofibrillar protein FSR in vivo in humans using conventional continuous phenylalanine and leucine tracer infusion protocols with the oral administration of intrinsically L-[1-
13
C]phenylalanine and L-[1-
13 C]leucine-labeled micellar casein.
METHODS

Subjects.
Eleven older men with well-controlled Type 2 diabetes (age: 71 Ϯ 1 y; body wt: 79 Ϯ 2 kg; body mass index: 26 Ϯ 0.6 kg·m Ϫ2 ) were examined in the current study. The subjects were part of a larger ongoing investigation being conducted in our laboratory. Participants were informed of the purpose of the study, experimental procedures, and all its potential risks prior to providing written informed consent to participate. Participants had no history of participation in any stable isotope amino acid tracer experiments prior to this experiment. The study was approved by the Medical Ethics Committee of the Maastricht University, Maastricht, The Netherlands, and conformed to standards for the use of human subjects in research as outlined in the fifth Declaration of Helsinki.
Experimental protocol. Subjects were instructed to refrain from vigorous physical activity for 3 days prior to the tracer infusion. All subjects consumed a standardized meal of the same composition [providing 55 energy% (En%) carbohydrate, 30 En% fat, and 15 En% of protein] the evening prior to the tracer infusion. Subjects reported to the laboratory at 0800 h following an overnight fast. A Teflon catheter was inserted into an antecubital vein for the primed infusion. A second Teflon catheter was inserted into a dorsal hand vein of the contralateral arm and placed in a hot box (60°C) for arterialized blood sampling. After baseline blood collection (t ϭ Ϫ210 min), the plasma phenylalanine and leucine pools were primed with a single intravenous dose of L-[ring-2 H5]phenylalanine (2 mol/kg) and L-[1-13 C]leucine (4 mol/kg), after which the continuous L-[ring-2 H5]phenylalanine and L- [1- 13 C]leucine infusion was initiated (0.05 and 0.10 mol·kg Ϫ1 ·min Ϫ1 , respectively). The L-[1-13 C]leucine prime was modified to 4 mol/kg from the more commonly used 7.6 mol/kg to minimize the anabolic influence of leucine administration on muscle protein synthesis. Muscle biopsies were collected for the measurement of postabsorptive muscle protein synthesis rates (t ϭ Ϫ120 and 0 min). Immediately after the second biopsy, subjects ingested a single bolus of 20-g intrinsically L- [1- 13 C]phenylalanine and L- [1- 13 C]leucine-labeled casein dissolved in 350-ml vanilla flavored water. Additional biopsies were collected at t ϭ 120 and 300 min for the measurement of postprandial muscle protein synthesis rates. The biopsies were collected from the middle region of the vastus lateralis (15 cm above the patella) with a Bergstrom needle under local anesthesia. All biopsy samples were freed from any visible adipose tissue and blood, immediately frozen in liquid nitrogen, and stored at Ϫ80°C until subsequent analysis. Multiple blood samples were collected during the infusion and were processed as previously described (7) (Fig. 1) .
Production (6, 26, 34) . The milk was heated to 50°C and converted to skim milk (the cream was removed) before being microfiltrated using a membrane with a pore size of 1.4 M at 50°C to remove microbes. Subsequently, the skim milk was microfiltrated on a 0.2-M pore size diameter membrane to separate the casein micelles from the soluble whey proteins at 55°C. The casein micelles were concentrated, diafiltrated with pure water, pasteurized, and stored at Ϫ40°C. 15 N]tyrosine were added to the samples. The plasma was deproteinized on ice with 10 mg of dry 5-sulfosalicylic acid. Free amino acids were purified using cation exchange chromatography (AG 50W-X8 resin; Bio-Rad, Hercules, CA). The free amino acids were converted to their tert-butyl dimethylsilyl (TBDMS) derivative before analysis by GC-MS. The amino acid concentrations were determined using electron impact ionization by monitoring ions at mass/charge (m/z) 302 and 308 for unlabeled and [U-
13 C6]-leucine, respectively, 336 and 346 for unlabeled and [U- isotope effects that occur during analysis. Phenylalanine and leucine enrichments were corrected for the presence of both the 13 C and 2 H isotopes. Plasma isotopic enrichment of the t-BDMS derivative of ␣-[
13 C]ketoisocaproate acid (␣-KIC) was measured by GC-MS analysis for use as a surrogate for leucyl-tRNA labeling (36) .
Muscle analyses. The muscle intracellular free amino acids were extracted from 50 mg of wet muscle tissue. The muscle was homogenized on ice with a Teflon-coated pestle using ice-cold 2% perchloric acid (7 l ϫ wet wt) and then centrifuged at 10,000 g at 4°C for 5 min. The supernatant was then collected, and this process was repeated 2 more times. The supernatant was taken as the muscle intracellular free amino acid pool and processed in the same manner as the plasma samples for isotopic enrichment by GC-MS analysis.
Myofibrillar protein enriched fractions were extracted from a separate piece of 50-mg wet muscle tissue by hand-homogenizing on ice using a Teflon pestle in a standard extraction buffer (7.5 l/mg) (19) . The samples were spun at 1,500 g for 10 min at 4°C. The resultant supernatants that contained the sarcoplasmic proteins were removed. The remaining myofibrillar and collagen pellet were washed with 500 l of extraction buffer and spun at 700 g for 10 min at 4°C. The myofibrillar proteins were solubilized by adding 1.5 ml of 0.3 M NaOH and heating at 50°C for 30 min with vortex mixing every 10 min. Samples were centrifuged at 10,000 g for 5 min at 4°C, and the supernatant containing the myofibrillar-enriched fraction was collected, and the collagen pellet was discarded. Myofibrillar proteins were precipitated by the addition of 1 ml of 1 M perchloric acid and spinning at 700 g for 10 min at 4°C. The myofibrillar-enriched proteins were washed twice with 70% ethanol. Amino acids were liberated by the addition of 2 ml of 6 M HCL and heated at 110°C for 24 h. The hydrolyzed myofibrillar protein fraction was dried under a nitrogen stream while being heated to 120°C and, subsequently, dissolved in a 25% acetic acid solution and passed over a Dowex exchange resin (AG 50W-X8, 100 -200 mesh hydrogen form; BioRad). The free amino acids from the myofibrillar protein pellet were eluted with 2 M NH 4OH and dried. The purified amino acids were divided into 2 aliquots to determine the L-[ring-
2 H5]phenylalanine enrichments by GC-MS analysis and the L-[1-
13 C]phenylalanine and L- [1- 13 C]leucine enrichments by gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS) analysis.
To reduce the signal-to-noise ratio during GC-MS analysis at low tracer enrichments, the phenylalanine from the myofibrillar protein hydrolysates was enzymatically decarboxlated to ␤-phenylethylamine (9) prior to TBDMS derivatization (32, 33) . Enrichments of the protein-bound samples were determined by selected ion monitoring for phenylalanine mass to charge ratio at 183 (m ϩ 5) to 180 (m ϩ 2) and a single linear standard curve (to avoid slope influences on the measured TTR) from mixtures of known m ϩ 5 to m ϩ 0 ratios. To avoid saturation of the MS and eliminate bias due to any potential concentration dependencies (22) , the split ratio was adjusted prior to the injection of each sample so that nearly equal amounts of phenylalanine were injected for all samples and standards.
The remaining aliquot of purified amino acids were converted to their N(O,S)-ethoxycarbonyl ethyl esters derivatives to determine the L-[1-
13 C]phenylalanine and L-[1-13 C]leucine labeling of the myofibrillar proteins by GC-C-IRMS analysis (Trace GC Ultra, IRMS model MAT 253; Thermo Scientific, Bremen, Germany). The derivatized amino acids were separated on a 30 m ϫ 0.25 mm ϫ 0.25 m DB-5MS column (temperature program: 120°C for 10 min; 3°C/min ramp to 150°C; 30°C/min ramp to 300°C; hold for 5 min) prior to combustion. Standard regression curves were applied from a series of known standard enrichment values against the measured values to assess the linearity of the mass spectrometer and to account for any isotope fractionation which may have occurred during the analysis.
Calculations. The FSR of the myofibrillar proteins were calculated using the standard precursor product equation: FSR (%/h) ϭ ⌬Ep/ [Eprecursor ϫ t] ϫ 100, where ⌬Ep is the change in phenylalanine or leucine labeling between two muscle biopsies, Eprecursor is the average labeling over time curve (AUC) of the precursor pools (plasma or muscle free), and t indicates the tracer incorporation time (hours) between two muscle biopsies.
Statistics. A within-subject repeated measures design was used for the current study. Differences in myofibrillar protein FSR between tracers were tested using a two-factor (condition ϫ time) analysis of variance (ANOVA) with repeated measures on time. Specifically, the tracer approach (intravenous leucine, intravenous phenylalanine, and the orally ingested phenylalanine) is the condition, and time factor is the myofibrillar protein synthetic response at the various repeated time points (i.e., postabsorptive, 0 -2 h, and 2-5 h time factors). The same analysis was performed to identify differences between the postabsorptive vs. the 0 -5 h postprandial time points. Plasma amino acid concentrations were analyzed using one-factor (time) ANOVA. Where significant interactions were identified in the ANOVA, Tukey's post hoc test was performed to determine differences between means for all significant main effects and interactions. Linear regression lines were fitted to the precursor pool enrichments to assess the existence of any deviation in enrichment indicated by lines with a significant positive or negative slope. Pearson's r product moment correlation was used to examine associations between measured variables. All data are expressed as means Ϯ SE. For all analyses, statistical significance was set at P Ͻ 0.05.
RESULTS
Plasma amino acid concentrations. Plasma leucine concentrations increased after protein ingestion and returned to baseline values by 180 min (Fig. 2A) . The same pattern was observed in the plasma phenylalanine concentrations, but a return to postabsorptive values was observed by 90 min in the postprandial phase (Fig. 2B) . Precursor pool enrichments. Linear regression analysis indicated that the slopes of the extracellular plasma-free L-[1-13 C]leucine enrichment over time curve for both the postabsorptive (t ϭ Ϫ120 to 0 min) and postprandial (t ϭ 0 to 300 min) phases were not different from zero (P ϭ 0.09 and 0.22) (Fig. 3A) . The same result was observed in the plasma ␣-KIC enrichments for both the postabsorptive (P ϭ 0.17) and postprandial periods (P ϭ 0.27). There was a significant correlation between the plasma ␣-KIC enrichments and the plasma L-[1-13 C]leucine enrichments during the infusion (r ϭ 0.9, P Ͻ 0.0001). The muscle intracellular free L-[1-
13 C]leucine enrichments did not vary over the infusion trial (P ϭ 0.09).
The slope of the plasma-free L-[ring-2 H 5 ]phenylalanine enrichments were not significantly different from zero during the postabsorptive (t ϭ Ϫ120 to 0 min) phase (P ϭ 0.07), but the slopes were significantly different from zero after protein ingestion (P Ͻ 0.0001) (Fig. 3B) . However, the muscle intracellular free L-[ring-2 H 5 ]phenylalanine enrichments did not differ from zero over the infusion (P ϭ 0.22).
The plasma L-[1-13 C]phenylalanine enrichments rapidly increased after protein ingestion and the enrichments remained elevated for 150 min in the postprandial phase (Fig. 3C) . Similarly, the muscle intracellular free L-[1-
13 C]phenylalanine labeling was increased at both 120 and 300 min during the postprandial period compared with the values observed prior to protein ingestion (P Ͻ 0.05).
Myofibrillar protein enrichments. Presented in Table 1 are the incremental changes in the myofibrillar protein-bound enrichments during the postabsorptive and postprandial phases between the various infused and ingested tracers.
Myofibrillar protein synthesis rates. Postabsorptive myofibrillar protein FSR did not differ between the primed continuous infusion of L-[ring-2 H 5 ]phenylalanine or L-[1-
13 C]leucine (P ϭ 0.8) (Fig. 4) . The FSR calculated over the entire postprandial phase (0 -300 min) was greater following protein ingestion based on plasma-free ␣-KIC (P ϭ 0.04) and plasma L-[1-
13 C]leucine enrichments (P ϭ 0.03) compared with the postabsorptive values (Fig. 4) . The postprandial myofibrillar protein FSR calculated on the muscle-free leucine enrichment tended to be greater after protein ingestion compared with postabsorptive values at 0 -300 min (P ϭ 0.057). There were no significant increases in the postprandial myofibrillar protein FSR compared with postabsorptive values at any time point (or precursor pool value) based on the continuous infusion of L-[ring- 
DISCUSSION
Our previous efforts have demonstrated the feasibility of the production of intrinsically labeled milk proteins with enrichments that exceed 35 MPE (26) . In this study, we show it is possible to produce doubly labeled milk proteins that will allow for the assessment of dietary protein digestion and absorption kinetics without disturbing steady-state tracer conditions for the calculation of postprandial muscle protein FSR and the concomitant assessment of de novo muscle protein accretion from the ingested protein source. Other workers have produced intrinsically labeled milk proteins with low enrichments (8 -10 MPE) to maintain tracer steady state following bolus protein ingestion during constant infusions (1, 28, 29) , but this approach does not allow for the assessment of dietary protein digestion and absorption kinetics or the assessment of the metabolic fate of the ingested protein that is used for de novo muscle protein accretion. vided us with an effective strategy to omit the impact of dietary protein ingestion on the dilution of the L-[1-
13 C]leucine labeling of the precursor pools during a primed constant infusion (Fig. 3A) and is likely responsible for the differential estimations of the postprandial muscle protein synthetic response between the tracer conditions. Muscle protein synthesis rates can vary substantially based upon the study design applied, tracer selection, and/or the choice of precursor pool. Also, it has been shown that the GC-C-IRMS is the preferred method to measure 13C-labeled amino acid enrichments in skeletal muscle tissue (5) . Transfer RNA (tRNA)-charged amino acids are the direct precursors for muscle protein synthesis. In the "ideal" experiment, the tRNAbound amino acids would be used as the precursor for the determination of muscle protein synthesis rates, but it is analytically difficult to measure the tRNA-bound with the specific amino acid tracer(s) (27, 37) . Thus the enrichment of the plasma-or muscle-free amino acid pools are generally used as an index for the aminoacyl-tRNA enrichment, and these provide lower and upper limits of muscle protein FSR, respectively. The transamination product of leucine (␣-KIC) is often used as surrogate for the leucyl-tRNA during leucine tracer infusions. This approach is usually referred to as the reciprocal pool model (20, 31) . There is no reciprocal pool model for phenylalanine tracers since phenylalanine is broken down by hydroxylation to tyrosine. The most accessible precursor pool enrichment for the calculation of muscle protein synthesis is the plasma-free or muscle-free enrichment following the infusion of a phenylalanine tracer. The use of these precursor pools with a phenylalanine tracer provides the lower and upper limits of muscle proteins synthesis, respectively. Here, the precursor pool L-[ring-2 H 5 ]phenylalanine enrichments were disturbed following the ingestion of protein. The plasma-free pool allows a more representative definition of the level of tracer dilution compared with the muscle-free enrichments, as more frequent sampling of plasma allows a more detailed assessment of the tracer dilution over time. However, the FSR based on the plasma-free or muscle-free enrichment both resulted in a lower potential to detect differences in the postprandial stimulation of muscle protein synthesis rates. Therefore the maintenance of tracer "steady state" during a continuous infusion after the ingestion of dietary protein should not be overlooked.
In the past, we have demonstrated the value of using milk proteins intrinsically labeled with L-[1- (12, 16, 18, 23, 24, 25) . Our previous work (12, 16, 18, 23, 24, 25) and that of the majority of other research groups trying to assess the postprandial muscle protein synthetic response to the ingestion of a single bolus of protein may provide a low estimate for the postprandial muscle protein synthetic response based on the intravenous infusion of L-[ring- 2 H 5 ]phenylalanine (or any other amino acid tracer) as a result of isotopic dilution of the plasma precursor pool. However, significant differences in postprandial muscle protein synthesis rates based on the intravenous L-[ring-2 H 5 ]phenylalanine infusions are generally observed between various treatments and seem to support previous measurements (12, 23, 25) . In many of our recent efforts we also assessed the postprandial muscle protein synthetic response by determining the metabolic fate of dietary protein-derived L-[1-
13 C]phenylalanine into skeletal muscle protein, which is not dependent on steady-state equations and, as such, remains unaffected by fluctuations in plasma L-[ring-2 H 5 ]phenylalanine enrichment (12, 23, 24) . The present data imply that when precursor dilutions occur, the subsequent ability to detect measureable differences in the "estimated" postprandial muscle protein synthetic response may be minimized when calculations are based upon the intravenous L-[ring-2 H 5 ]phenylalanine infusion due to plasma precursor dilution. The application of doubly labeled proteins will allow for the assessment of dietary protein digestion and absorption kinetics and prevents the tracer dilution from occurring, thereby optimizing the assessment of the postprandial muscle protein synthetic rate based on the primed continuous amino acid tracer infusion.
Recently, we have reported on the use of highly labeled milk proteins, without the administration of intravenous tracer infusions, to assess the change in the mixed muscle-bound L-[1-13 C]phenylalanine enrichments (⌬MPE) over the postprandial phase (14, 15, 35) . Here, we matched our previous efforts in the production of milk proteins labeled with large amounts of L-[1-
13 C]phenylalanine (ϳ39 MPE) (26, 34) and show it is possible to measure changes in the L-[1-
13 C]phenylalanine enrichments in the myofibrillar-bound fraction (Table 1) . This methodology is convenient as the tracer is delivered orally as a constituent of the protein meal and therefore widens the potential to study the effects of protein meal manipulations to settings where intravenous infusions are not easily applied (e.g., sports or clinical hospital settings). The muscle-bound tracer enrichments are a product of synthesis and true precursor pool availability. The values from the intravenous tracers are reflective of the infusion rate and the overall amino acid content of skeletal muscle protein (Table 1) . For example, human muscle protein is ϳ4% phenylalanine and ϳ9% leucine by total amino acid content, and thus the greater ⌬MPE with leucine is expected. The muscle protein-bound L-[1-
13 C]phenylalanine enrichment derived from the orally ingested tracer gives an indication of the metabolic fate of dietary proteinderived amino acids toward de novo muscle protein deposition. As such, the dietary protein-derived amino acid tracer incorporation allows for direct insight into the anabolic potential of a protein containing meal (12, 15, 24, 35) .
Here, we also reported the FSR values based on the casein derived L-[1-
13 C]phenylalanine and simply compared these values with the estimated FSRs based on the primed continuous intravenous infusions. It is not surprising that the protein meal-derived FSR did not relate to the absolute FSRs based on the primed continuous intravenous tracer infusions. The precursor pool enrichments were substantially different between the ingested and intravenous tracers during the postprandial phase (Fig. 3) . Absolute FSR values are determined by their tracer delivery method and the associated precursor pool enrichment used for the FSR calculations. The choice of the most "reliable" precursor pool to use for the meal-derived tracer FSR is problematic. For example, both the plasma-free and muscle-free precursor pools were not in equilibrium with the phenylalanyltRNA (as in the flooding dose method) and/or in a tracer steady state (as in the constant infusion method). It is important to emphasize that the orally ingested tracer approach used in the current study differs from the "classic" flooding dose method (11) . The tracer is delivered as a natural component of the micellar casein (i.e., ϳ360 mg L- [1- 13 C]phenylalanine per 20 g of protein) and not intravenously injected with other unlabeled free amino acids. Thus the casein derived L-[1-
13 C]phenylalanine did not rapidly equilibrate the isotopic enrichment among the extracellular, intracellular, or aminoacyl-transfer pools, as is generally targeted when applying the flooding dose method. We acknowledge that the orally ingested tracer calculations do not provide quantitative values for the muscle protein FSR based on the phenylalanyl-tRNA enrichment, but this idea is the same for the existing methods used for the calculation of muscle protein FSR. The available established methods (e.g., flood, subflood, and constant infusion) used for the determination of muscle protein FSR have limitations/assumptions associated with them, and most simply provide an estimated value for the absolute muscle protein FSR (23, 24) . Overall, the application of highly labeled milk proteins and the subsequent measurement of muscle proteinbound L-[1-
13 C]phenylalanine tracer incorporation (⌬MPE) in human intervention trials provides a direct method to assess the use of dietary protein-derived amino acid for muscle protein accretion. This approach can be used with or without the concomitant use of intravenous tracers to provide another marker of the anabolic response to food ingestion (12, 35) .
From an application perspective, the use of doubly labeled milk protein provides a tool to assess the various secondary factors (e.g., protein digestion/absorption, splanchnic extraction, and subsequent amino acid availability) that have been shown to influence the postprandial muscle protein synthetic response and to maintain steady-state precursor pool enrichments after the ingestion of a protein meal. The latter provides the optimal conditions for the use of precursor product equations for the calculation of muscle protein FSR. The production of intrinsically labeled milk proteins may be beyond the capacity of many laboratories in the field of in vivo human metabolic research, but this does not discredit its relevance in research. Instead, collaborative ventures should be pursued to allow for a more economically viable production and more widespread use. Certainly, dairy cows are large mammals, and their associated resource cost and management is challenging. Therefore, other helpful options are to produce labeled food proteins on a smaller scale by using smaller farm animals (e.g., goats or chickens) (2, 10) . Of course, the use of intrinsically labeled food protein also allows us to assess the relevance of previous work in the field using more contemporary tracer approaches and extends our insight in this field.
In conclusion, we demonstrated that the stimulation of postprandial muscle protein synthesis rates may differ if tracer steady-state conditions are disturbed. The combined use of primed continuous intravenous tracer infusions with the ingestion of doubly labeled dairy protein provides the possibility to assess postprandial muscle protein FSR under steady-state precursor enrichments. The use of doubly labeled milk proteins also provides a means to assess postprandial amino acid kinetics and the subsequent use of the dietary protein-derived amino acids for de novo muscle protein accretion.
